BioSpace News Archive

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced that Moody’s Investors Service (“Moody’s”) upgraded the unsecured rating of Bio-Rad Laboratories, Inc. senior unsecured notes to Baa2 from Baa3

Integrated DNA Technologies (IDT) announces that it has entered into a strategic cooperation with ChosenMed Technology (Beijing) Co., Ltd (ChosenMed), a medical sequencing firm focused on personalized medicine and transformation healthcare in China.

Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, notes the announcement made today by Sierra Oncology (“Sierra”), the licence holder for novel oral Chk1 inhibitor SRA737, that it is exploring non-dilutive strategic options to support the future continued development of its portfolio of potent and selective DDR (DNA Damage Response) assets, including SRA737.

Ovid Therapeutics Inc. (NASDAQ: OVID), today announced that following a Type C Meeting with the U.S. Food and Drug Administration(FDA), it has initiated the pivotal Phase 3 NEPTUNE trial with OV101, a novel delta (δ)-selective GABAA receptor agonist, in Angelman syndrome

CryoTherapeutics GmbH and CryoTherapeutics SA today announced the closing of its B round of financing.

Members of the National Science Teachers Association have approved a new name for the organization that better reflects the numerous stakeholders in the K-16 science teaching community and the many places where science learning takes place.

Trial showed statistically-significant and clinically meaningful benefit in patients with the most aggressive type of lung cancer

According to Coherent Market Insights, global blow-fill-seal (BFS) packaging services in healthcare market was valued at US$ 240.2 million in 2017 and is projected to exhibit a CAGR of 6.9% over the forecast period (2018–2026).

UnitedHealthcare has launched UnitedHealthcare Hearing, offering all consumers, including people enrolled in the company’s individual, employer-sponsored and Medicare Advantage plans, greater access to affordable, quality hearing health.

Nearly 80 nephrologists, cardiologists, diabetologists, patients and policy makers will gather in Chicago this week to share information about a human protein called sodium-glucose contransporter-2 (SGLT2), its role in diabetic kidney disease and how a new drug class called SGLT2 inhibitors can help.